Advenchen Laboratories
Advenchen is the small Californian company that discovered anlotinib, the multi-kinase inhibitor that became one of China's most used cancer pills, and it leads late-stage trials of related compounds.
Overview
Advenchen Laboratories, based in Moorpark, California, designs kinase inhibitors and licenses them to partners. Its anlotinib (AL3818), licensed to Chia Tai Tianqing, is approved in China for lung cancer, soft tissue sarcoma, medullary thyroid cancer and small cell lung cancer, and Advenchen itself sponsors phase 3 trials of anlotinib and catequentinib outside China. Its records appear on ClinicalTrials.gov under the Advenchen name.
Scorecard
All companies- approved products +6
- targets +6
- modalities +2
- regions +1
- registry trials +30
Similar pages
not linked directly; found by shared links- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyPeregrine Pharmaceuticals (now Avid Bioservices)
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.